Patrick J. Mcenany - Aug 20, 2021 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
President and CEO, Director
Signature
/s/ Patrick J. McEnany
Stock symbol
CPRX
Transactions as of
Aug 20, 2021
Transactions value $
-$139,581
Form type
4
Date filed
8/24/2021, 05:01 PM
Previous filing
Aug 17, 2021
Next filing
Dec 6, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $250K +80K +1.65% $3.12* 4.93M Aug 20, 2021 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$299K -54.2K -1.1% $5.52 4.87M Aug 20, 2021 Direct F1, F2
transaction CPRX Common stock, par value $0.001 per share Options Exercise $374K +120K +2.46% $3.12* 4.99M Aug 23, 2021 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$465K -82.6K -1.65% $5.63 4.91M Aug 23, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -80K -2.32% $0.00 3.37M Aug 20, 2021 Common Stock 80K $3.12 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -120K -3.56% $0.00 3.25M Aug 23, 2021 Common Stock 120K $3.12 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold to cover exercise price of options and tax withholding requirements.
F2 Shares were sold in various lots from $5.455 to $5.601 per share. The listed sale price represents a weighted average price for the shares sold.
F3 Shares were sold in various lots from $5.59 to $5.675 per share. The listed sale price represents a weighted average price for the shares sold.
F4 Options vested in three annual tranches beginning on August 28, 2015.